Colossal Biosciences seeks $20B–$30B valuation in new funding talks
The five-year-old firm, which has begun selling conservation technology to the US and UAE, is reportedly in discussions to raise capital at a significantly higher valuation than its last round.
De-extinction startup Colossal Biosciences is reportedly in discussions to raise new capital at a valuation of $20 billion to $30 billion, according to a report by Axios. This potential valuation represents a doubling or tripling of the company’s previous $10.2 billion valuation. The five-year-old company has not disclosed the size of the round or the identity of the lead investor.
The shift in valuation comes as the Dallas-based firm begins generating revenue. Over the last 12 months, Colossal has offered its conservation technology to the US government and the United Arab Emirates. The UAE recently invested $60 million in the company, marking a tangible commercialisation of its scientific capabilities beyond its core de-extinction research.
Colossal has expanded its operational footprint through three spun-out startups. Breaking focuses on breaking down plastics, while Form Bio is a computational biology platform that secured $30 million in funding. Astromech, an AI-driven predictive modelling company focused on biology and life sciences, was valued at $2 billion in March. These ventures diversify the parent company’s portfolio beyond its primary mission of resurrecting extinct species.
The company continues to advance its de-extinction efforts, adding the bluebuck antelope as its sixth target species in late April. Its nonprofit arm, the Colossal Foundation, recently partnered with the University of Tasmania to protect Tasmanian devils from contagious facial cancer. CEO Ben Lamm has also indicated that the company’s artificial animal womb technology is expected to be ready for use next year, with potential applications in human fertility treatment.
This fundraising effort occurs amidst a broader boom in longevity tech, alternative energy, and other deep-tech sectors. Colossal did not respond to requests for comment regarding the new valuation talks. The company’s core science, which has previously targeted the woolly mammoth and the dodo bird, may eventually generate revenue through the sale of biodiversity credits, a market-based mechanism similar to carbon credits.
